全文获取类型
收费全文 | 323330篇 |
免费 | 28364篇 |
国内免费 | 11701篇 |
专业分类
耳鼻咽喉 | 2783篇 |
儿科学 | 4741篇 |
妇产科学 | 5341篇 |
基础医学 | 54985篇 |
口腔科学 | 7429篇 |
临床医学 | 23582篇 |
内科学 | 39683篇 |
皮肤病学 | 4763篇 |
神经病学 | 20982篇 |
特种医学 | 11290篇 |
外国民族医学 | 73篇 |
外科学 | 29228篇 |
综合类 | 47736篇 |
现状与发展 | 54篇 |
一般理论 | 10篇 |
预防医学 | 18436篇 |
眼科学 | 5410篇 |
药学 | 37668篇 |
107篇 | |
中国医学 | 16834篇 |
肿瘤学 | 32260篇 |
出版年
2024年 | 236篇 |
2023年 | 3885篇 |
2022年 | 5684篇 |
2021年 | 11646篇 |
2020年 | 10636篇 |
2019年 | 10146篇 |
2018年 | 10193篇 |
2017年 | 11479篇 |
2016年 | 12247篇 |
2015年 | 12403篇 |
2014年 | 16434篇 |
2013年 | 21906篇 |
2012年 | 17698篇 |
2011年 | 20904篇 |
2010年 | 14998篇 |
2009年 | 14964篇 |
2008年 | 16707篇 |
2007年 | 17895篇 |
2006年 | 16646篇 |
2005年 | 14944篇 |
2004年 | 12773篇 |
2003年 | 11029篇 |
2002年 | 8842篇 |
2001年 | 7861篇 |
2000年 | 6604篇 |
1999年 | 5573篇 |
1998年 | 4408篇 |
1997年 | 4299篇 |
1996年 | 3908篇 |
1995年 | 3956篇 |
1994年 | 3694篇 |
1993年 | 3077篇 |
1992年 | 2695篇 |
1991年 | 2505篇 |
1990年 | 2132篇 |
1989年 | 1880篇 |
1988年 | 1731篇 |
1987年 | 1562篇 |
1986年 | 1393篇 |
1985年 | 2007篇 |
1984年 | 1688篇 |
1983年 | 1227篇 |
1982年 | 1384篇 |
1981年 | 1099篇 |
1980年 | 991篇 |
1979年 | 834篇 |
1978年 | 555篇 |
1977年 | 451篇 |
1976年 | 414篇 |
1975年 | 251篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
84.
刘光 ' target='_blank'> 刘支娜 ' target='_blank'> 张玲 ' target='_blank'> 王会瑟 ' target='_blank'> 蔺颐 ' target='_blank'> 张亚涛 ' target='_blank'> 陶金 ' target='_blank'> 刘闯 ' target='_blank'> 《现代肿瘤医学》2021,(2):323-326
目的:探讨基于脉压变异度(PPV)的目标导向液体治疗(GDFT)在腹膜后巨大恶性肿瘤切除术患儿中的应用。方法:择期行腹膜后巨大恶性肿瘤切除术患儿64例,年龄0.5~3岁,ASA Ⅱ-Ⅲ级。随机将患儿分为目标导向液体治疗组(G组)和常规液体治疗组(C组),每组32例。G组以PPV为指导,根据GDFT方案进行液体管理,C组采用常规液体管理。记录手术开始(T1)、手术开始后1 h(T2)、手术结束(T3)的MAP、CVP、PPV、Lac值、TNF-α、IL-6浓度。记录术中输注晶体液量、胶体液量、液体总量、出血量、尿量、手术时间、多巴胺使用率以及排气时间、术后住院时间和恶心呕吐发生率。结果:G组输注晶体液量显著少于C组(P<0.05),而输注胶体液量显著多于C组(P<0.05)。两组术中输注液体总量、出血量、尿量与多巴胺使用率方面差异无统计学意义。T2、T3时刻,G组PPV、TNF-α、IL-6显著低于C组(P<0.05),而两组间MAP、CVP、Lac在各时点差异无统计学意义。G组术后排气时间明显短于C组(P<0.05),而在术后恶心呕吐发生率和住院时间方面两组差异无统计学意义。结论:PPV指导的GDFT可以应用于腹膜后巨大恶性肿瘤切除术患儿,能维持其血流动力学稳定,减少炎症因子IL-6、TNF-α释放,促进胃肠功能恢复,但对术后转归无明显影响。 相似文献
85.
Bortezomib is a novel proteasome inhibitor, which has been successfully used to treat mantle cell lymphoma and multiple myeloma. However, the direct effects of bortezomib on acute promyelocytic leukaemia (APL) have not been fully investigated. In the present study, the WST-8 assay, western blotting, flow cytometry, monodansylcadaverine staining and transmission electron microscopy were performed. It was demonstrated that bortezomib treatment induced a time- and dose-dependent decrease in the viability of NB4 cells. Bortezomib treatment induced cell apoptosis in NB4 cells, as assessed by Annexin V/propidium iodide analysis, and the detection of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, Bax and Bcl-2 expression. Furthermore, bortezomib treatment induced autophagy in NB4 cells, as indicated by autophagosome formation, p62 degradation, LC3-I to LC3-II conversion and formation of acidic autophagic vacuoles. Notably, autophagy induced by bortezomib was initiated prior to apoptosis. Inhibition of autophagy by knocking down Beclin-1 expression increased bortezomib-induced apoptosis in NB4 cells. Therefore, the present study revealed that the combination of bortezomib and autophagy inhibition may be a potential treatment strategy for APL. 相似文献
86.
苏影 《中国继续医学教育》2021,(1)
目的探讨眼睑恶性肿瘤切除术中应用Z形皮瓣及推进皮瓣I期修复眼睑缺损的临床效果。方法将50例眼睑恶性肿瘤切除术患者按不同缝合方法分为两组,即对照组25例,术中直接缝合;观察组25例,术中行Z形皮瓣及推进皮瓣I期修复;比较两组眼睑修复效果。结果观察组术后皮瓣成活率96.0%、切口Ⅰ期愈合率100%、修复满意率92.0%,均高于对照组的72.0%、68.0%、56.0%,差异有统计学意义(P<0.05)。观察组术后并发症发生率低于对照组,但差异无统计学意义(P>0.05)。结论眼睑恶性肿瘤切除术中眼睑缺损修复时,采用Z形皮瓣及推进皮瓣,眼睑修复良好,患者修复满意率高,值得推广应用。 相似文献
87.
IntroductionHip displacement is common in cerebral palsy (CP) and is related to the severity of neurological and functional impairment. It is a silent, but progressive disease, and can result in significant morbidity and decreased quality of life, if left untreated. The pathophysiology of hip displacement in CP is a combination of hip flexor-adductor muscle spasticity, abductor muscle weakness, and delayed weight-bearing, resulting in proximal femoral deformities and progressive acetabular dysplasia. Due to a lack of symptoms in the early stages of hip displacement, the diagnosis is easily missed. Awareness of this condition and regular surveillance by clinical examination and serial radiographs of the hips are the key to early diagnosis and treatment.Hip surveillance programmesSeveral population-based studies from around the world have demonstrated that universal hip surveillance in children with CP allows early detection of hip displacement and appropriate early intervention, with a resultant decrease in painful dislocations. Global hip surveillance models are based upon the patients’ age, functional level determined by the Gross Motor Function Classification system (GMFCS), gait classification, standardized clinical exam, and radiographic indices such as the migration percentage (MP), as critical indicators of progressive hip displacement.ConclusionDespite 25 years of evidence showing the efficacy of established hip surveillance programmes, there is poor awareness among healthcare professionals in India about the importance of regular hip surveillance in children with CP. There is a need for professional organizations to develop evidence-based guidelines for hip surveillance which are relevant to the Indian context. 相似文献
88.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
89.
Pauline A. J. Mendelaar Jaco Kraan Mai Van Leonie L. Zeune Leon W. M. M. Terstappen Esther Oomende Hoop John W. M. Martens Stefan Sleijfer 《Molecular oncology》2021,15(1):116
Circulating tumor cells (CTCs) in the blood of cancer patients are of high clinical relevance. Since detection and isolation of CTCs often rely on cell dimensions, knowledge of their size is key. We analyzed the median CTC size in a large cohort of breast (BC), prostate (PC), colorectal (CRC), and bladder (BLC) cancer patients. Images of patient‐derived CTCs acquired on cartridges of the FDA‐cleared CellSearch® method were retrospectively collected and automatically re‐analyzed using the accept software package. The median CTC diameter (μm) was computed per tumor type. The size differences between the different tumor types and references (tumor cell lines and leukocytes) were nonparametrically tested. A total of 1962 CellSearch® cartridges containing 71 612 CTCs were included. In BC, the median computed diameter (CD) of patient‐derived CTCs was 12.4 μm vs 18.4 μm for cultured cell line cells. For PC, CDs were 10.3 μm for CTCs vs 20.7 μm for cultured cell line cells. CDs for CTCs of CRC and BLC were 7.5 μm and 8.6 μm, respectively. Finally, leukocytes were 9.4 μm. CTC size differed statistically significantly between the four tumor types and between CTCs and the reference data. CTC size differences between tumor types are striking and CTCs are smaller than cell line tumor cells, whose size is often used as reference when developing CTC analysis methods. Based on our data, we suggest that the size of CTCs matters and should be kept in mind when designing and optimizing size‐based isolation methods.
Abbreviations
- ACCEPT
- Automated CTC Classification, Enumeration, and PhenoTyping software
- BC
- breast cancer
- BLC
- bladder cancer
- CD
- computed diameter
- CEL
- cultured tumor cell (cell line)
- CK
- cytokeratin
- CRC
- colorectal cancer
- CTC‐L
- circulating tumor cells derived from cerebrospinal fluid (liquor)
- CTCs
- circulating tumor cells
- DAPI
- 4′6‐diamidino‐2‐phenylindole
- EMT
- epithelial–mesenchymal transition
- EpCAM
- epithelial cell adhesion molecule
- IQR
- interquartile range
- KW test
- Kruskal–Wallis test
- MWU test
- Mann–Whitney U test
- NCR
- nucleus/cytoplasm ratio
- P2A
- perimeter to area
- PC
- prostate cancer
- TIF
- tagged Image Format files
- TXT
- text file
- μm
- micrometer
- µm2
- square micrometers
90.
肿瘤防控是当今世界性一大难题,目前我国每年新发肿瘤病例即将突破400万。近年来,我国肿瘤总体发病率和死亡率呈现逐年上升趋势,肿瘤的高死亡率和低治愈率已严重威胁我国居民健康,很大程度影响了患者的生存质量,大大降低患者的生活水平,危害患者的身心健康。中医认为,肿瘤发病的病因复杂,病机变化多端,是内外因相互影响、相互作用的结果。若在外邪作用于人体之初,及时辨证施治,防止伏邪入里发生传变,将大大减少肿瘤疾病的发生和发展。因此,外邪理论与肿瘤的发病机制亟待进一步探究。在中国知网(CNKI),Public Medline(PubMed)数据库中以外感、邪气、中医、肿瘤、发病机制等关键词进行检索,本文共纳入67篇中英文文献为参考,对外邪理论与肿瘤发病机制进行全面探讨。强调了外邪在肿瘤发病中的重要作用,以及中医药在早期防治肿瘤中具有显著的优势。外邪如风邪、寒邪、湿邪、火邪、从口鼻皮表而入的邪气等因素,使得肿瘤的发生更具复杂性。中医药可以在肿瘤发展早期进行有效的防护和干预,可大大提高防病抗肿瘤的目的,减少肿瘤的发生、发展、传变,使临床用药更有效、更精准、更具靶向性,不至使肿瘤的治疗错失良机,为临床治疗肿瘤提供更明确的指导方向。 相似文献